NasdaqCM:MYOS

Stock Analysis Report

Executive Summary

MYOS RENS Technology Inc. focuses on the discovery, development, and commercialization of nutritional and therapeutic products that enhance muscle health and performance.

Snowflake

Fundamentals

Mediocre balance sheet with limited growth.


Similar Companies

Share Price & News

How has MYOS RENS Technology's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-0.7%

MYOS

-0.5%

US Personal Products

1.0%

US Market


1 Year Return

16.1%

MYOS

22.2%

US Personal Products

6.7%

US Market

Return vs Industry: MYOS underperformed the US Personal Products industry which returned 22.2% over the past year.

Return vs Market: MYOS exceeded the US Market which returned 6.7% over the past year.


Share holder returns

MYOSIndustryMarket
7 Day-0.7%-0.5%1.0%
30 Day-2.0%-1.0%-1.8%
90 Day-14.7%1.0%-1.8%
1 Year16.1%16.1%24.0%22.2%9.1%6.7%
3 Year-4.0%-4.0%43.6%36.3%46.1%36.6%
5 Year-85.4%-85.4%87.0%68.2%66.9%48.6%

Price Volatility Vs. Market

How volatile is MYOS RENS Technology's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is MYOS RENS Technology undervalued based on future cash flows and its price relative to the stock market?

4.09x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Undervalued: Insufficient data to calculate MYOS's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate MYOS's fair value to establish if it is undervalued.


Price Based on Earnings

PE vs Industry: MYOS is unprofitable, so we can't compare its PE Ratio to the Personal Products industry average.

PE vs Market: MYOS is unprofitable, so we can't compare its PE Ratio to the US market.


Price Based on Expected Growth

Low PEG Ratio: Insufficient data to calculate MYOS's PEG Ratio to determine if it is good value.


Price Based on Value of Assets

PB vs Industry: MYOS is overvalued based on its PB Ratio (4.1x) compared to the US Personal Products industry average (3.6x).


Next Steps

Future Growth

How is MYOS RENS Technology expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

82.0%

Forecasted annual revenue growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Earnings vs Savings Rate: Insufficient data to determine if MYOS's forecast earnings growth is above the savings rate (2.7%).

Earnings vs Market: Insufficient data to determine if MYOS's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: MYOS's revenue (82% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: MYOS's revenue (82% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Estimates


Future Return on Equity

High Future ROE: Insufficient data to determine if MYOS's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has MYOS RENS Technology performed over the past 5 years?

8.1%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: MYOS is unprofitable, but has reduced losses over the past 5 years at a rate of 8.1% per year.

Accelerating Growth: Unable to compare MYOS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MYOS is unprofitable, making it difficult to compare its past year earnings growth to the Personal Products industry (21%).


Return on Equity

High ROE: MYOS has a negative Return on Equity (-96.07%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: MYOS is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: MYOS is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is MYOS RENS Technology's financial position?


Financial Position Analysis

Short Term Liabilities: MYOS's short term assets ($3.0M) exceeds its short term liabilities ($1.1M)

Long Term Liabilities: MYOS's short term assets (3.0M) exceeds its long term liabilities (172.0K)


Debt to Equity History and Analysis

Debt Level: MYOS's debt to equity ratio (24.1%) is considered satisfactory

Reducing Debt: MYOS's debt to equity ratio has increased from 0.03% to 24.1% over the past 5 years.


Balance Sheet

Inventory Level: MYOS has a high level of physical assets or inventory.

Debt Coverage by Assets: MYOS's debt is covered by short term assets (assets are 3.819100x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MYOS has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: MYOS has less than a year of cash runway if free cash flow continues to grow at historical rates of 11.8% each year.


Next Steps

Dividend

What is MYOS RENS Technology's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage3.3%forecastin3Yearsn/a

Current dividend yield vs market & industry


Dividend Yield and Payments Analysis

Notable Dividend: Unable to evaluate MYOS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate MYOS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if MYOS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MYOS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MYOS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of MYOS RENS Technology's salary, the management and board of directors tenure and is there insider trading?

2.2yrs

Average management tenure


CEO

Joe Mannello (61yo)

2.2yrs

Tenure

US$70,710

Compensation

Mr. Joseph Mannello, also Known as Joe, has been the Chief Executive Officer of MYOS RENS Technology Inc. since August 24, 2017 and served as its Interim Chief Executive Officer from September 1, 2016 to A ...


CEO Compensation Analysis

Compensation vs. Market: Joe has recently become CEO, making it difficult to compare their total compensation against companies of similar size in the US market.

Compensation vs Earnings: Joe's compensation has been consistent with company performance over the past year.


Management Age and Tenure

2.2yrs

Average Tenure

60yo

Average Age

Experienced Management: MYOS's management team is considered experienced (2.2 years average tenure).


Board Age and Tenure

4.8yrs

Average Tenure

58.5yo

Average Age

Experienced Board: MYOS's board of directors are considered experienced (4.8 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$50,00127 Mar 19
Christopher Pechock
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares34,247
Max PriceUS$1.46
BuyUS$250,00027 Mar 19
Joseph Mannello
EntityIndividual
Role
Chief Executive Officer
CEO & Director
Shares171,233
Max PriceUS$1.46

Ownership Breakdown


Management Team

  • Bob Hariri (60yo)

    Chairman of Board & Chairman of the Scientific Advisory Board

    • Tenure: 7.5yrs
    • Compensation: US$15.56k
  • Magshoud Dariani

    Chief Technology Officer

    • Tenure: 0yrs
  • Joe Mannello (61yo)

    CEO & Director

    • Tenure: 2.2yrs
    • Compensation: US$70.71k
  • Ren Ren (57yo)

    Global Chairman

    • Tenure: 3.6yrs
    • Compensation: US$14.69k
  • Joseph DiPietro

    Controller

    • Tenure: 3.1yrs
  • Kris Ohrenick

    Head of Marketing

    • Tenure: 1.8yrs
  • Dante Carnevale

    Chief Strategist

    • Tenure: 0.2yrs

Board Members

  • Victor Mandel (54yo)

    Independent Director

    • Tenure: 3.2yrs
    • Compensation: US$42.50k
  • Bob Hariri (60yo)

    Chairman of Board & Chairman of the Scientific Advisory Board

    • Tenure: 7.5yrs
    • Compensation: US$15.56k
  • Chris Pechock (54yo)

    Independent Director

    • Tenure: 5.7yrs
    • Compensation: US$42.50k
  • Louis Aronne (63yo)

    Independent Director & Member of Scientific Advisory Board

    • Tenure: 8.3yrs
    • Compensation: US$27.78k
  • Caroline Apovian

    Member of Scientific Advisory Board

    • Tenure: 6.7yrs
  • Joe Mannello (61yo)

    CEO & Director

    • Tenure: 2.2yrs
    • Compensation: US$70.71k
  • Neilank Jha

    Member of Scientific Advisory Board

    • Tenure: 7.8yrs
  • John Nosta (60yo)

    Independent Director

    • Tenure: 2.8yrs
    • Compensation: US$32.78k
  • Ren Ren (57yo)

    Global Chairman

    • Tenure: 3.6yrs
    • Compensation: US$14.69k
  • Eric Zaltas (56yo)

    Independent Director

    • Tenure: 0.8yrs

Company Information

MYOS RENS Technology Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: MYOS RENS Technology Inc.
  • Ticker: MYOS
  • Exchange: NasdaqCM
  • Founded: 2007
  • Industry: Personal Products
  • Sector: Household
  • Market Cap: US$13.297m
  • Shares outstanding: 9.17m
  • Website: https://www.myosrens.com

Number of Employees


Location

  • MYOS RENS Technology Inc.
  • 45 Horsehill Road
  • Suite 106
  • Cedar Knolls
  • New Jersey
  • 7927
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MYOSNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDSep 2008
73MDB (Deutsche Boerse AG)YesCommon StockDEEURSep 2008

Biography

MYOS RENS Technology Inc. focuses on the discovery, development, and commercialization of nutritional and therapeutic products that enhance muscle health and performance. The company primarily focuses on d ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/14 02:19
End of Day Share Price2019/10/11 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

© 2018 SIMPLY WALL STREET PTY LTD, COMMUNITY DESIGN 2845206, US DESIGN PATENT #29/544/281, EUROPEAN DESIGN REGISTRATION #2845206, STANDARD & POOR’S FINANCIAL SERVICES LLC. ALL RIGHTS RESERVED.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2018, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2018)